Income Tax

Karnataka High Court rules tax officers may independently audit pharmaceutical conference sponsorships

Originally reported by Taxscan as: Income Tax Dept can Independently Examine Pharma Company's Conference Sponsorship Expenses Despite ACPMP Reprimand: Karnataka HC [Read Order]

20 Nov 2026, 9:24 am IST · Xecute.finance News DeskArchive edition

The crisp read

The Karnataka High Court held that tax authorities possess the legal authority to independently investigate conference sponsorship expenses incurred by pharmaceutical firms. The court clarified that determinations made by the Apex Committee for Pharma Marketing Practices do not legally bind income tax officials.

Xecute Impact Breakdown

For CAs

  • Tax professionals advising pharmaceutical clients must ensure all conference sponsorship deductions are thoroughly backed by independent primary documentation, attendance records, and proof of business.
  • Tax officers retain unhindered jurisdiction to evaluate the commercial expediency and tax deductibility of conference sponsorship expenditures under the tax statute, regardless of ACPMP findings.

For businesses

  • Pharmaceutical companies can no longer argue that sectoral committee clearances suffice for tax purposes regarding conference sponsorship expenses.
  • Businesses must prepare for independent financial scrutiny by the Income Tax Department on conference sponsorship expenses claimed, notwithstanding any reprimands or evaluations by the Apex Committee for Pharma Marketing Practices.

Deep dive – the full story

The Karnataka High Court ruled that the Income Tax Department holds the legal mandate to independently examine conference sponsorship expenses claimed by pharmaceutical companies, regardless of any findings issued by the Apex Committee for Pharma Marketing Practices (ACPMP). The judicial bench clarified that reprimands or evaluations conducted by the ACPMP do not restrict or bind tax authorities from conducting their own independent financial scrutiny. In tax practice, business promotion and conference sponsorship expenses claimed by drug manufacturers frequently face regulatory scrutiny regarding compliance with medical ethics codes and allowable business deductions.

The old position often saw companies arguing that sectoral committee clearances sufficed for tax purposes, whereas the new position affirmed by the court ensures that tax officers retain unhindered jurisdiction to evaluate the commercial expediency and tax deductibility of such expenditures under the tax statute. Tax professionals advising pharmaceutical clients must ensure that all conference sponsorship deductions are thoroughly backed by independent primary documentation, attendance records, and proof of business purpose rather than relying solely on sectoral clean chits.

Compliance teams should track judicial trends concerning medical marketing expenditures and maintain separate audit trails for tax and regulatory bodies. Ultimately, pharmaceutical firms must prepare for dual-layer scrutiny where regulatory clearances do not exempt them from independent tax investigations.

Source: taxscan.in

This is news/educational content, not investment advice. Xecute.finance is not SEBI-registered. Consult a qualified professional before acting.

More from the Xecute news desk

Reading the archive edition.

This story has retired from the live feed - the full text stays here permanently. The live app adds the newest desk, Ask Xecute, deadline trackers and the daily quiz.

Open this story in the Xecute app →